This is a news story, published by Ars Technica, that relates primarily to AstraZeneca news.
For more physics news, you can click here:
more physics newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best science news, business news, entertainment news, and much more. If you like physics news, you might also like this article about
Radiation therapy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest radiopharmaceuticals news, radiopharmaceutical drug development news, physics news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
RadiationArs Technica
•86% Informative
Targeted radiopharmaceuticals deliver radioactive warheads directly at the tumor site.
AstraZeneca completed its purchase of Fusion Pharmaceuticals in a deal worth up to $2.4 billion .
Only a handful of these therapies are commercially available for patients.
Expanding the reach of the therapy to treat a broader array of cancers will also require harnessing new kinds of tumor-killing particles.
VR Score
86
Informative language
85
Neutral language
51
Article tone
informal
Language
English
Language complexity
75
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
11
Source diversity
10
Affiliate links
no affiliate links